Pancreaticogastrostomy: A Salvage Procedure for Pancreatic Body and Neck Resection

Ang Li, Pankaj Prasoon, Wu Hong, Hui Min Lu, Zhao Da Zhang, Zhang Zhaoda

1 Department of Hepatobiliary Pancreatic Surgery, West China Hospital, Sichuan University, Sichuan Province, China

* Corresponding author: Zhang Zhaoda, Department of Hepatobiliary Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China. Tel: +86-2885422475, Fax: +86-2885422475, E-mail: zhangzhaoda@hotmail.com

ABSTRACT

The purpose of this analysis was to evaluate the technological viability, basic safety and consequence of central pancreatectomy (CP) with pancreaticogastrostomy in properly chosen sufferers with noncancerous central pancreatic pathology. This research is centered on the infirmary charts of West China hospital. We recruited 20 individuals from 2007 to 2009 diagnosed with benign cancerous growth of pancreatic body and neck. They underwent pancreatic body and neck resection adhering to pancreaticogastrostomy. We carried out central pancreatectomy following pancreaticogastrostomy in 20 patients: 8 with serous cyst adenomas, 11 with mucinous cystadenomas, and 1 with neuroendocrine tumor. The position of all tumors was restricted to body and neck of the pancreas, measuring a mean ± standard deviation of 2.64±3.2 cm. The mean post-operative hospital stay was 7 days (ranging from 6 to 16 days). There was no intraoperative additional complications. From a technical perspective, CP is a safe and sound, pancreas-preserving pancreatectomy for non-enucleable non-cancerous pancreatic pathology restricted to the pancreatic body.

Keywords: Central Pancreatectomy; Pancreaticogastrostomy

1. Introduction

Benign lesions of the neck and proximal body of the pancreas offer a problematic operative obstacle. If the lesions are not responsive to straightforward enucleation, specialists might be confronted with the alternative of executing pancreatectoduodenectomy or distal pancreatectomy to incorporate the lesion, ensuing in resection of a sizeable quantity of regular pancreatic parenchyma. Central pancreatic resection has been documented.

With Roux-en-Y pancreaticojejunostomy reconstruction; nevertheless, this interferes with small bowel continuity and necessitates a supplemental anastomosis. Pancreaticogastrostomy (PG) has been explored in the last several years as a substitute renovation approach when compared with pancreaticojejunostomy (PJ), being encouraged by quite a few experts (1,2). Delcore et al. revealed a procedure of PG in which 2 to 3 cm of the pancreatic remnant was telescoped into the gastric lumen. They revealed 0% incidence of pancreatic fistula following this approach (3). Numerous prospective benefits of PG have been formerly endorsed. They incorporate the deterrence of pancreatic enzyme activation by gastric acidity and also technological facets associated to the vicinity of the pancreas to the gastric wall and diminished anastomosis in a single jejunal loop. The outstanding blood supply, the breadth of the gastric wall, and draining of the abdomen by means of nasogastric tubing suction symbolize supplemental positive aspects in favor of PG. This research is to appraise the operative outcomes of pancreaticogastrostomy.

2. Case Report

Twenty sequential affected individuals underwent CP and DP from February 2007 to June 2009. There were 8...
women and 12 men, with the mean age of 65 ± 20 years. During their admission, almost all patients’ representing symptoms were abdominal pain, back or flank pain, along with gastroesophageal reflux disease with an unforeseen finding of a pancreatic neoplasm or cyst in the course of examination to rule out their chief grievance (Table 1).

Table 1. Demographic data of all included patients

| Patients | Age  | Gender | History                     | Main complaint | Pathology         |
|----------|------|--------|-----------------------------|----------------|-------------------|
| 1        | 55   | M      | Hypertension                | Abdominal pain | Cystic neoplasm  |
| 2        | 46   | F      | Endometriosis               | Abdominal pain | Cystic neoplasm  |
| 3        | 47   | M      | Hypertension/Pneumonia      | Pancreatits    | Cystic neoplasm  |
| 4        | 73   | M      | TCC/Afib/hypertension/CHF   | Incidental     | Cystic neoplasm  |
| 5        | 48   | F      | Hypertension/Pneumonia      | Pancreatits    | Cystic neoplasm  |
| 6        | 73   | M      | TCC/Afib a/hypertension/CHF | Incidental     | Cystic neoplasm  |
| 7        | 51   | F      | Asthma/radiculoapathy       | Incidental     | Cystic neoplasm  |
| 8        | 50   | M      | Gastroesophageal reflux disease | Incidental | Cystic neoplasm  |
| 9        | 45   | M      | Hypertension                | Flank pain     | Cystic neoplasm  |
| 10       | 63   | F      | Osteoarthritis/cholelithiasis | Back pain | Cystic neoplasm  |
| 11       | 38   | M      | None                        | Incidental     | Cystic neoplasm  |
| 12       | 67   | M      | Asthma/COPD                 | Incidental     | Cystic neoplasm  |
| 13       | 68   | M      | Gastroesophageal reflux disease | Incidental | Cystic neoplasm  |
| 14       | 71   | M      | Abdominal pain              | Incidental     | Cystic neoplasm  |
| 15       | 68   | M      | Hypertension                | Incidental     | Cystic neoplasm  |
| 16       | 59   | M      | Abdominal pain, Anxiety     | Incidental     | Cystic neoplasm  |
| 17       | 46   | F      | Abdominal pain, vomiting    | Incidental     | Cystic neoplasm  |
| 18       | 54   | F      | Osteoarthritis/cholelithiasis | Back pain | Cystic neoplasm  |
| 19       | 65   | M      | Hypertension, CCF          | Incidental     | Cystic neoplasm  |
| 20       | 59   | M      | Abdominal pain              | Incidental     | Cystic neoplasm  |

*a Abbreviations: Afib: Atrial fibrillation; CAD: coronary artery disease; CCF: congestive cardiac failure

In order to guideline their chief complaints, two of them had been suspected of having malignant lesion on the pancreatic body on the basis of CT scan but sooner or later intraoperative histopathological final results revealed noncancerous lesions in all subjects. It is unlikely that any of the 20 patients had been diagnosed with type 2 diabetes mellitus before operations with the exception of just one who was suffering from depressive disorders and was using antidepressive medications once in a while.

2.1. Surgical Technique

Ten patients were managed by means of midline incisions, ten through left subcostal incisions; four of them were operated for gallstones disease via open approach, so we went for midline incision in course to prevent wound dehiscence and assist in apparent anatomical view for resection.

The dissection begins with division of the gastrocolic ligament with entry into the lesser sac. Small vessels were ligated by 4-0 silk suture and whereever it was required,
coagulation was utilized. The pancreas was then scrutinized with intraoperative ultrasonography (VIVID 4) for recognition of the neoplasm and specifying its relationship to the portal vein and superior mesenteric vein. The pancreatic dissection was performed inferiorly along the superior mesenteric vein. A tunnel was produced at the pancreatic neck; splitting the parenchyma from the posterior superior mesenteric vein/portal vein confluence. The cephalad aspect of the pancreas was then dissected from the posterior meandering splenic artery. Using four stay sutures in the cephalic and caudal parenchyma for hemostasis, the pancreas was then divided between stay sutures to the right of the lesion. The stumps of the neck of the pancreas was oversewn with polypropylene suture in continuous running fashion. The proximal pancreatic duct was not oversewn independent of the main body of the pancreas (Figure 1).

The body and tumor were then elevated from the posteriorly coursing splenic artery and vein. Many small tributaries were divided during this dissection with clips and fine polypropylene ligature. After accomplishing a satisfactory distal border, two additional haemostatic stay stitches were inserted in the distal remnant parenchyma, and the pancreas was divided into the left side of the tumor. Dissected sections were attained in all cases for pathological analysis to rule out any discharge relevant additional complications. Three were readmitted for pancreatitis. There was no pancreatic leakage at anastomotic site. We supervised all the patients with contrast USG who complained of severe abdominal pain during postoperative period to ascertain there is not any hemorrhage from anastomotic site. We supervised all the patients with contrast USG who complained of severe abdominal pain during postoperative period to ascertain there is not any hemorrhage from anastomotic site. We supervised all the patients with contrast USG who complained of severe abdominal pain during postoperative period to ascertain there is not any hemorrhage from anastomotic site.

2.2. Intra-operative Findings

Twenty CP were carried out within standard anesthesia. Prior to induction of anesthesia, there was an attempt to accomplish a smooth induction. There were no intraoperative complications, with the exception of one experienced slight hypotension and there was not any blood transfusion in all cases. Operative mortality was zero. The mean anesthesia time ± SD was 313 ± 96 minutes, and the mean operative time ± SD was 222 ± 58 minutes. The mean operative blood loss ± SD was 690 ± 510 mL. Two patients underwent CP with excision of the small cyst at the right lateral and left lateral lobe of the liver correspondingly. Cystic resection and hemostasis had been done by fine prolene suture. A left flank incision for transitional cell carcinoma. In all cases, the spleen had been preserved. Mean volume of resection SD was 35.7-20.4 cm³. The mean greatest dimension of tumor ± SD was 2.6 ± 1.3 cm. The tumor size was evaluated by Vivid 4 ultrasonogarpy device. All resected tumors were sent for pathological analysis and confirmed to be cystic neoplasm of various types after histopathological evaluation (Table 2).

2.3. Post-operative Results

Twenty CP with PG were performed, with zero mortality (95% CI 0 to 25%) and 25% morbidity (95% CI 12.9 to 43.7%). Postoperative complications incorporated 4 substantial pyrexia with urinary tract infections and two were readmitted for pancreatitis. The mean initial postoperative volumes but we found there is less secretion of amylase (30IU/L) comparable to amylase levels in the serum. The considerable release was due to the left disinfectant agent which came out through the drainage tube. It could possibly be due to inappropriate suction prior to concluding the abdominal wall or in obese patients there is considerably excess fat and suction of all disinfectant is rather challenging owing to substantial unwanted fat content material.

Closed-suction water flow and drainage tubes were taken out in all patients ahead of being allowed to go devoid of any discharge relevant additional complications.
Table 2. Operative characteristics of all patients

| Patients | Incision Choice | Anesthesia Time(mins) median | Operation Time(mins) median | Blood Loss(ml) median | Size of Resection(cm) median | Tumor Size(cm) median | Tumor Pathology                           |
|----------|-----------------|-----------------------------|-----------------------------|-----------------------|-----------------------------|----------------------|------------------------------------------|
| 1        | LSC             | 230                         | 170                         | 755                   | 14.5                        | 1.2                  | Serous oligocystic adenoma               |
| 2        | Midline         | 240                         | 185                         | 690                   | 12.6                        | 1.0                  | Mucinous cystadenoma                     |
| 3        | Midline         | 255                         | 210                         | 735                   | 11.7                        | 1.1                  | Serous microcystic adenoma               |
| 4        | Midline         | 245                         | 205                         | 640                   | 43.8                        | 3.2                  | Mucinous cystadenoma                     |
| 5        | Midline         | 260                         | 220                         | 705                   | 38.6                        | 2.9                  | Serous microcystic adenoma               |
| 6        | LSC             | 255                         | 190                         | 800                   | 44.8                        | 3.6                  | Neuroendocrine/glucagonoma               |
| 7        | Midline         | 250                         | 215                         | 650                   | 30.8                        | 2.9                  | Mucinous cystadenoma                     |
| 8        | Midline         | 310                         | 270                         | 900                   | 49.5                        | 3.4                  | Mucinous cystadenoma                     |
| 9        | Midline         | 280                         | 235                         | 995                   | 50.6                        | 4.0                  | Mucinous cystadenoma                     |
| 10       | Midline         | 265                         | 220                         | 755                   | 47.3                        | 3.8                  | Mucinous cystadenoma                     |
| 11       | LSC             | 215                         | 175                         | 680                   | 15.6                        | 1.7                  | Serous oligocystic adenoma               |
| 12       | Midline         | 310                         | 275                         | 1050                  | 85.3                        | 5.3                  | Serous microcystic adenoma               |
| 13       | Midline         | 295                         | 250                         | 895                   | 63.9                        | 5.0                  | Serous microcystic adenoma               |
| 14       | Midline         | 310                         | 270                         | 765                   | 45.7                        | 3.9                  | Mucinous cystadenoma                     |
| 15       | LSC             | 355                         | 310                         | 1100                  | 69.4                        | 4.3                  | Mucinous cystadenoma                     |
| 16       | Midline         | 380                         | 340                         | 1060                  | 70.5                        | 5.6                  | Serous microcystic adenoma               |
| 17       | Midline         | 354                         | 305                         | 900                   | 39.2                        | 3.2                  | Serous microcystic adenoma               |
| 18       | Midline         | 340                         | 295                         | 980                   | 37.9                        | 3.0                  | Mucinous cystadenoma                     |
| 19       | Midline         | 265                         | 210                         | 865                   | 43.9                        | 3.6                  | Mucinous cystadenoma                     |
| 20       | Midline         | 270                         | 224                         | 700                   | 22.8                        | 1.8                  | Mucinous cystadenoma                     |
Perioperative somatostatin was administered subcutaneously to all patients for a mean ± SD of 2.7 ± 1.4 days (ranging from 1 to 6 days). Median lengths of hospital stay and postoperative stay were 7.5 days (ranging from 6 to 17 days; mean ± SD, 8.0 ± 3.6 days, 7.9 ± 3.4 days, respectively). It is unlikely that any of the 20 patients were aware of the clinical symptoms of exocrine insufficiency, but 2 developed late onset glucose intolerance as noticeable by elevated glycosylated hemoglobin levels. There were no cancerous growth recurrences with the median follow up of 19 months (ranging from 1 to 39 months).

2.4. Post-operative Follow-up

Of the 20 patients, 2 developed glucose intolerance during the follow up period. This diagnosis was made by identifying borderline elevated glycosylated hemoglobin levels. In either instances, the tumors were 5.6 and 4.3 cm in size, and the volumes of resection were comparatively little substantial as effectively as the affected individual acquired chronic pancreatitis. We deemed that perhaps because of the reduction of the significant section of the pancreatic remnant and chronic pancreatitis was the related variables for that. In our research, we integrated complete blood profile preoperatively to rule out if any individual has diabetes and coagulation disorders or any sort of viral or microbial infection. We noticed one most intriguing issue; two patients were discharged early in comparison to other patients. Considering that all guidelines ended up within our control although they discharged from hospital. But in the course of follow up, they showed pancreaticogenic type 2 diabetes. In our study, all patients had regular follow up (Figure 2). Two patients reported abdominal distension right after taking heavy and greasy foods, having burning up feeling beneath the xiphoid process once in a while. Endoscopic examination exposed and ruled out gastric ulcer.

We interrogated for the affiliated variables of ulcer; following a comprehensive track record they explained that following the surgical treatment they drank and smoked cigarette on a regular basis. We labeled may be alcoholic beverages and cigarette smoking qualified prospects of gastric ulcer. Triple antibiotics therapy was prescribed for three weeks and they were advised to give up hot and spicy foodstuff and alcoholic beverages even more. Rest of the patients experienced ordinary daily life and probably none of them reported any type of complaint which we needed to pay particular attention.

3. Discussion

In the 21st century, technological improvement and excellent preoperative and postoperative critical care are foremost most highly processed consequences of post-surgical outcomes. In our analysis, pancreaticogastrostomy minimized the morbidity and mortality when there was the concern of central or distal pancreatectomy for benign tumors. On the other hand, in the current study, basic safety of PG was predominantly based on technological factors of the pancreaticogastric anastomosis. The so-called joining procedure in which a small posterior-wall gastrotomy linked with a running second stratum, which sways the gastric mucosa to the pancreatic serosa, constituted the key technological determine to protect against pancreatic leaking. Earlier postoperative hemorrhage after PG can come about frequently from the anastomotic site or from the trim borders of the pancreas. This complication constantly necessitates relaparotomy to regulate the hemorrhaging vessels (3,4). PG revealed an additional advantageous early on outcome than PJ. PG is encouraged for specialists who come across challenges with PJ for renovation following PD. Having said that, our study was primarily conducted to determine the practicability and surgical consequences of PG. Yeo et al. conducted the very first prospective randomized study of PG vs PJ. They documented that the likelihood of PF was 12.3% in the PG group and 11.3% in the PJ group and that PG did not minimize the incidence of PF when compared to PJ. However, they have not used a telescoped or invaginated technique (5). Watanabe et al. publicized in the Japan Pancreas Surgery Group survey of 511 pancreaticogastrostomy and 2483 pancreaticojejunostomy patients. There had been no substantial dissimilarities between pancreaticogastrostomy and pancreaticojejunostomy with admiration to the occurrence rates of intrabdominal hemorrhage and abscess or mortality (6). The approach of PG has a number of prospective positive aspects in excess of PJ. Very first, the PG anastomosis can be conducted effortlessly due to the fact that the posterior wall of the stomach lies right away anterior to the mobilized pancreatic remnant and is commonly broader than the transected pancreas. Secondly, with PG, the pancreatic exocrine secretions get into the most likely acidic gastric setting, precluding the digestive system deterio-
ration of the pancreatoenteric anastomosis by activated proteolytic enzymes. In comparison with PJ, the triggering of pancreatic exocrine secretions can come about much more easily in the existence of intestinal enterokinase and bile. Thirdly, PG stays away from the long jejunal loop where the pancreatobiliary secretions gather for the duration of the very early postoperative period of time. Moreover, postoperative gastric decompression can offer continuous elimination of pancreatic and gastric secretions preventing deposition and consequently tension on the anastomosis. Finally, PG anastomosis lowers the quantity of anastomoses in one loop of the maintained jejunal loop, which most likely diminishes the probability of loop kinking. The scientific studies have preferred PG over PJ despite the fact that these scientific studies are constrained by their modest patient communities (7,8).

Central pancreatectomy with pancreaticogastrostomy rennovation is safe and sound and from a technical perspective it ought to be regarded as a secure reconstruction approach following central pancreatectomy for noncancerous ailment. Duct-to-mucosa pancreaticogastrostomy may possibly be a harmless and efficient approach for protecting against pancreatic fistula progression immediately after distal pancreatectomy when executed by knowledgeable specialists who are competent in this procedure.

Acknowledgements
None declared.

References
1. Oussoultzoglou E, Bachellier P, Bigourdan JM, Weber JC, Nakano H, Jaeck D. Pancreaticogastrostomy decreased relaparotomy caused by pancreatic fistula after pancreaticoduodenectomy compared with pancreaticojejunostomy. Arch Surg. 2004;139(3):327-35.
2. Bradbeer JW, Johnson CD. Pancreaticogastrostomy after pancreaticoduodenectomy. Ann R Coll Surg Engl. 1990;72(4):266-9.
3. Delcore R, Thomas JH, Pierce GE, Hermreck AS. Pancreateogastrostomy: a safe drainage procedure after pancreatoduodenectomy. Surgery. 1999;108(4):644-5.
4. Kim SW, Youk EG, Park YH. Comparison of pancreateogastrostomy and pancreaticojunostomy after pancreatoduodenectomy performed by one surgeon. World J Surg. 1997;21(6):640-1.
5. Yeo CJ, Cameron JL, Maher MM, Sauter PK, Zahirak MI, Talamini MA, et al. A prospective randomized trial of pancreateogastrostomy versus pancreaticojunostomy after pancreatoduodenectomy. Ann Surg. 1995;222(4):580-8.
6. Watanabe M, Usui S, Kajiwara H, Nakamura M, Sumiyama Y, Takeda T, et al. Current pancreatogastrointestinal anastomotic methods: results of a Japanese survey of 3109 patients. J Hepatobiliary Pancreat Surg. 2004;11(1):25-33.
7. Fernandez-Cruz I, Cosa R, Blanco L, Lopez-Boado MA, Artidillo E. Pancreateogastrostomy with gastric partition after pylorus-preserving pancreateoduodenectomy versus conventional pancreateojunostomy: a prospective randomized study. Ann Surg. 2008;248(6):930-8.
8. Bassi C, Derenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138(1):8-13.